In this context, we present a unique case report of a patient with KRAS G12C-mutant metastatic NSCLC who developed resistance to sotorasib after a dose reduction due to liver toxicity—a common issue in patients previously treated with immunotherapy before KRAS G12C inhibitors. Here, KRAS is linked to non-small cell lung carcinoma.